VIVO Cannabis has partnered with Linneo Health, a subsidiary of Alcaliber S.A., to be its European medical cannabis supply partner. Linneo Health, that recently received its EU-GMP (Good Manufacturing Practices) certification from the Spanish regulatory authorities. The agreement is a multi-year commitment, with increasing supply volumes as VIVO expands in the European medical market.
"Our partnership with Linneo Health is part of our strategic priority to accelerate international market growth," said Barry Fishman, Chief Executive Officer of VIVO. "We are excited to have an EU-GMP certified source of medical cannabis located within Europe. Through this partnership, we expect to be able to supply the European high-growth market with premium medical cannabis products and services. Our European based supply will allow VIVO to contribute to addressing the unmet medical needs of patients in Germany, which is one of our key target markets for international expansion."
In late March 2019, VIVO’s German subsidiary, ABcann Germany GmbH, was granted its pharmaceutical wholesale license and GDP-certificate by the responsible authorities of the state of Brandenburg. VIVO is now pursuing narcotic and import license applications in Germany to facilitate imports from other non-EU countries, including Canada, and expects to have its first products sold in the German market in early 2020.
In early February 2019, VIVO exported three of its proprietary cultivars, covering a broad range of cannabinoid profiles, to Linneo Health in Spain. "These cultivars were propagated to form VIVO’s genetic basis for commercial cultivation in Europe," the team with the company explains. "The agreement between ABcann Germany and Linneo Health is part of a long-term growth strategy of cooperation, the first step of which is the cultivation of EU-GMP certified cannabis, and represents the foundation on which VIVO and Linneo Health intend to complete the regulatory work required for the launch of medical cannabis in Europe, using a focused and phased approach."
For more information: